-
Vedolizumab Outperformed Infliximab in Real-World Outcomes
16 Jun 2025 03:51 GMT
… bowel diseases requiring advanced treatment—real world comparative effectiveness … ).
They extracted evaluable characteristics, treatment details, sequences, and outcomes from … with adalimumab (ADA) (1,260), golimumab (GOL) (111), infliximab (IFX) …
-
How to opt for potentially more affordable medications when treating some autoimmune or autoinflammatory diseases
05 Jun 2025 16:18 GMT
… any vaccines.
Also tell your doctor about all the medicines … or SIMPONI® (golimumab). Tell your doctor if you have ever … the US by AbbVie Biotechnology Ltd; Organon is … Biologics: More Treatment Choices. US Food and Drug Administration; Updated …
-
Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn’s Disease
30 May 2025 18:06 GMT
… trial,53 a fixed dose combination of guselkumab and golimumab … AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, … s disease: medical treatment. J Crohns … drugs for inflammatory bowel disease treatment-insights from phase II and III trials …
-
From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey
26 May 2025 11:06 GMT
… bDMARDs, anti-TNF (adalimumab, infliximab, golimumab, certolizumab, etanercept), anti-IL-6 … discontinuation of the drug due to side effects, patient-doctor request or … potential of personalized medicine driven by biomarkers to optimize treatment strategies is …
-
FDA Grants Ustekinumab-Aekn Interchangeability Designation for Stelara
07 May 2025 20:11 GMT
… of ustekinumab, including treatment of psoriatic arthritis, … to specialty high-cost medications.
“Interchangeability of Selarsdi … FDA, and they include AVT05, a proposed biosimilar for golimumab … Ustekinumab-aekn Receives FDA Approval. Drug Topics. April 19 …
-
Teva and Alvotech Gain FDA Interchangeability for SELARSDI Biosimilar to Stelara
06 May 2025 18:42 GMT
… S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech … U.S. Food and Drug Administration (FDA) has approved SELARSDI™ … product, including the treatment of adults and pediatric … the FDA: AVT05, a proposed biosimilar for Simponi (golimumab) and …
-
EULAR Task Force Expands Pregnancy-Safe Drug Options
07 May 2025 08:57 GMT
… with pregnancy. The teratogenic medications methotrexate, mycophenolate, and cyclophosphamide … drugs, the updated list of therapeutics is more reflective of treatment … , adalimumab, or golimumab), the Bacille Calmette−Guérin vaccine should be delayed …
-
FDA approves Selarsdi injection as interchangeable with Stelara
06 May 2025 10:35 GMT
… Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA … correspond with Stelara, including the treatment for both adult and pediatric … proposed biosimilar for Simponi (golimumab) and Simponi Aria (golimumab), AVT05, and AVT06 …
-
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05 May 2025 11:49 GMT
… Biotechnology Ltd. Eylea® is a registered trademark of Regeneron Pharmaceuticals … ustekinumab in clinical trials. The safety … live vaccines. Avoid administering BCG vaccines during treatment … .
Simponi® (golimumab) prescribing information. FDA product label. …
-
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05 May 2025 11:00 GMT
… Biotechnology Ltd. Eylea® is a registered trademark of Regeneron Pharmaceuticals … ustekinumab in clinical trials. The safety … live vaccines. Avoid administering BCG vaccines during treatment … .
Simponi® (golimumab) prescribing information. FDA product label. …
About
© 1995-2025